Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows lipid-based amphotericin B improves outcomes in non-HIV CM, suggesting better safety.
This retrospective cohort study compared the efficacy and safety of lipid-based amphotericin B formulations (amphotericin B colloidal dispersion (ABCD) and liposomal amphotericin B (L-AmB)) versus conventional amphotericin B deoxycholate (AmB-d) for the treatment of non-HIV-associated cryptococcal meningitis (CM). Data from 199 patients were analyzed, divided into three groups based on induction therapy: AmB-d (n = 110), ABCD (n = 44), and L-AmB (n = 45). At baseline, a higher proportion of patients in the lipid-based groups presented with altered mental status. After two weeks, the ABCD and L-AmB groups showed significantly better clinical improvement (as measured by BMRC Stage 1) compared to the AmB-d group (63.6% and 77.8% vs. 35.5%; P < 0.001), and experienced substantially lower rates of renal impairment (54.5% and 53.3% vs. 79.1%; P = 0.001). Early fungicidal activity (EFA) was similar across all groups. Multivariate analysis at 10 weeks indicated that both lipid-based formulations were associated with a lower risk of unsuccessful outcomes compared to AmB-d. Furthermore, one-year survival analysis for clinical cure demonstrated a significantly higher cumulative incidence in the lipid-based AmB groups (Log-rank test, P = 0.016). In conclusion, induction regimens based on ABCD or L-AmB were associated with better outcomes than AmB-d for non-HIV-associated CM, offering better long-term outcomes and a more favorable safety profile, particularly regarding kidney toxicity.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: